格隆汇10月9日｜艾德生物公告，10月9日，厦门艾德生物医药科技股份有限公司与深圳赛陆医疗科技有 限公司及其现有股东签署了《B轮增资协议》。艾德生物以现金方式向赛陆医疗增资5,000万元，其中 5.5701万元作为赛陆医疗新增注册资本，其余部分计入赛陆医疗资本公积金，本次增资后艾德生物持有 赛陆医疗2.3810%的股权。公司于2025年10月9日召开第四届董事会第八次会议，审议通过了《关于公 司对外投资的议案》。 ...

Core Viewpoint - The investment in Sailu Medical by Aide Biological is a strategic move to strengthen its position in the gene testing industry and enhance collaboration within the supply chain [1][2] Group 1: Investment Details - Aide Biological signed a B-round capital increase agreement with Sailu Medical, investing 50 million yuan, with 55,701 yuan allocated to the registered capital and the remainder to capital reserves [1] - Following this investment, Aide Biological holds a 2.3810% stake in Sailu Medical [1] Group 2: Industry Context - Sailu Medical operates in a technology-intensive sector with significant R&D barriers and has developed a self-controlled sequencing technology platform [1] - The company has full R&D and production capabilities for gene sequencing instruments and related consumables, with its SalusPro gene sequencer receiving national Class III medical device registration in January 2025 [1] - The national push for high-end medical equipment to be self-controlled and for import substitution presents strategic growth opportunities for domestic sequencing platform companies with core technologies [1] Group 3: Strategic Implications - The investment is a key strategic deployment for Aide Biological, aligning with the trends in the gene testing industry and enhancing supply chain collaboration [2] - The partnership will leverage Sailu Medical's core advantages in sequencing platforms and Aide Biological's expertise in tumor gene testing, creating a strong complementary effect [2] - This collaboration aims to improve the overall competitiveness of the company in the industry and promote resource integration, fostering a more self-controlled and collaborative industrial ecosystem [2] - The initiative is expected to accelerate innovation and clinical translation of cutting-edge technologies, providing more precise and accessible gene testing solutions for patients [2] - It will further solidify the company's leading position in the field of tumor precision medicine [2]

Core Viewpoint - The investment by the company in Sailu Medical is a strategic move to strengthen its position in the gene testing industry and enhance collaboration within the supply chain [1][2] Group 1: Investment Details - The company has signed a B-round capital increase agreement with Sailu Medical, investing 50 million yuan, of which 55,701 yuan will be added to the registered capital, and the remainder will be included in the capital reserve [1] - Following this investment, the company will hold a 2.3810% stake in Sailu Medical [1] Group 2: Industry Context - Sailu Medical operates in the upstream of the gene sequencing industry, characterized by high technical intensity and significant R&D barriers [1] - The company has developed a self-controlled sequencing technology platform and has complete R&D and production capabilities for gene sequencing instruments and related consumables [1] - The SalusPro gene sequencer received approval as a Class III medical device in January 2025 [1] Group 3: Strategic Implications - The investment aligns with the accelerating trend of domestic substitution in gene sequencing, leveraging Sailu Medical's core advantages in sequencing platforms [2] - This collaboration is expected to enhance the company's competitiveness in the industry and promote the integration of upstream and downstream resources [2] - The initiative aims to accelerate innovation and clinical transformation of cutting-edge technologies, providing more precise and accessible gene testing solutions for patients [2] - It will further solidify the company's leading position in the field of precision medicine for tumors [2]

二、董事会会议审议情况 1、审议通过《关于公司对外投资的议案》 表决结果：7票赞成，0票反对，0票弃权，本议案获表决通过。 2025年10月9日，艾德生物与深圳赛陆医疗科技有限公司（以下简称"赛陆 医疗""标的公司"）及其现有股东签署了《B轮增资协议》。艾德生物以现金方 式向赛陆医疗增资5,000万元，其中5.5701万元作为赛陆医疗新增注册资本，其余 部分计入赛陆医疗资本公积金，本次增资后艾德生物持有赛陆医疗2.3810%的股 权。 具体内容详见公司与本公告同日刊登在中国证监会指定的创业板信息披露 网站的"关于公司对外投资的公告"。 证券代码：300685 证券简称：艾德生物 公告编号：2025-044 厦门艾德生物医药科技股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第四届董事会第八次会议于2025年10月9日在厦门市海沧区鼎山路39号公司会议 室以通讯和现场表决相结合的方式召开，会议应到董事7人，实到董事7人，符合 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-045 厦门艾德生物医药科技股份有限公司 关于公司对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、对外投资概述 2025年10月9日，厦门艾德生物医药科技股份有限公司（以下简称"艾德生 物"或"公司"）与深圳赛陆医疗科技有限公司（以下简称"赛陆医疗""标的 公司"）及其现有股东签署了《B轮增资协议》。艾德生物以现金方式向赛陆医 疗增资5,000万元，其中5.5701万元作为赛陆医疗新增注册资本，其余部分计入赛 陆医疗资本公积金，本次增资后艾德生物持有赛陆医疗2.3810%的股权。 公司于2025年10月9日召开第四届董事会第八次会议，审议通过了《关于公 司对外投资的议案》。 根据《深圳证券交易所创业板股票上市规则》和《公司章程》的相关规定， 本次对外投资事项在公司董事会决策权限范围内，无需提交公司股东会审议。 本次对外投资不构成关联交易，不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 二、投资标的的基本情况 （一）标的公司基本信息 1、企业名称：深圳赛陆医疗科技有 ...

Core Viewpoint - The stock of Aide Biological experienced a decline of 2.04% on October 9, 2023, with a current price of 22.53 CNY per share and a market capitalization of 8.821 billion CNY, indicating a mixed performance in recent trading periods [1]. Financial Performance - For the first half of 2025, Aide Biological reported a revenue of 579 million CNY, representing a year-on-year growth of 6.69%, while the net profit attributable to shareholders was 189 million CNY, showing a significant increase of 31.41% [2]. - Cumulative cash dividends since the A-share listing amount to 421 million CNY, with 232 million CNY distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 5.41% to 25,300, with an average of 15,393 circulating shares per shareholder, a decrease of 5.13% [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 31.6706 million shares, which is a decrease of 3.5159 million shares from the previous period [3]. - New entrants among the top ten circulating shareholders include Huabao Zhongzheng Medical ETF, holding 9.0366 million shares [3]. Business Overview - Aide Biological, established on February 21, 2008, and listed on August 2, 2017, specializes in the research, production, and sales of molecular diagnostic products for precision oncology, along with related testing services [1]. - The company's revenue composition includes 83.43% from testing reagents, 9.84% from clinical research services, 5.61% from testing services, and 1.12% from other sources [1].

（文章来源：证券日报） 证券日报网讯艾德生物9月24日在互动平台回答投资者提问时表示，公司将持续加强与资本市场的沟 通。 ...

Core Viewpoint - The stock of Aide Biological has shown a slight increase of 1.56% year-to-date, with recent fluctuations indicating a decline over the past five and twenty trading days, while experiencing a rise over the last sixty days [2] Group 1: Stock Performance - On September 24, Aide Biological's stock rose by 2.01%, reaching a price of 22.85 CNY per share, with a trading volume of 84.03 million CNY and a turnover rate of 0.95%, resulting in a total market capitalization of 8.947 billion CNY [1] - Year-to-date, the stock has increased by 1.56%, with a decline of 2.18% over the last five trading days and 5.15% over the last twenty days, while showing a 7.38% increase over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Aide Biological reported a revenue of 579 million CNY, reflecting a year-on-year growth of 6.69%, and a net profit attributable to shareholders of 189 million CNY, which is a 31.41% increase compared to the previous year [2] - The company has distributed a total of 421 million CNY in dividends since its A-share listing, with 232 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, Aide Biological had 25,300 shareholders, an increase of 5.41% from the previous period, with an average of 15,393 circulating shares per shareholder, a decrease of 5.13% [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 31.67 million shares, a decrease of 3.52 million shares from the previous period, while Huabao Zhongzheng Medical ETF is a new fifth-largest shareholder with 9.04 million shares [3]

每经AI快讯，有投资者在投资者互动平台提问：请问公司储备的专利技术是否有新的科技成果转化？ 艾德生物（300685.SZ）9月24日在投资者互动平台表示，公司基于自主知识产权开发的多款产品目前正 处于注册申报阶段，其中包括已纳入创新医疗器械特别审批通道的HRD基因检测试剂盒，以及c-Met、 BRAF/TERT/RET/NTRK3基因突变检测等试剂盒。 （文章来源：每日经济新闻） ...

每经AI快讯，有投资者在投资者互动平台提问：贵司对目前拥有的30多个注册证是否做过这方面的资 产评估？ （记者 胡玲） 艾德生物（300685.SZ）9月24日在投资者互动平台表示，公司已获批的30余项医疗器械注册证暂未进行 相关资产评估。 ...